Key Drivers
- Profitability Improved
- Liquidity Strengthened
- Liabilities Elevated
AIAI Summary
CLOV has shifted from a survival story to a proof-of-durable-profitability investment: its rapid membership growth, expanding margins, positive free cash flow, and debt-free balance sheet support upside, but investors should require sustained medical-cost discipline and delivery on 2026 guidance before underwriting a lasting rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Improved
- •Liquidity Strengthened
- •Liabilities Elevated
CLOV's latest quarter shows a meaningful turnaround in profitability and cash flow with strong liquidity, but elevated liabilities, accumulated losses, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Modest upward trend
- •Post-peak pullback
- •Key level test
CLOV remains modestly constructive above its last-month average, but the 13% pullback from $5.10 signals caution unless it reclaims $4.66 resistance while holding $4.26–$4.30 support.
Sharp 13% pullback from the $5.10 high
Sentiment & News
Key News Insights:
- •Institutional Buying
- •AI Catalysts
- •Insider Selling
Clover Health drew institutional interest and highlighted PPO/AI growth catalysts, but insider-selling pressure and a 6.5% share decline signal near-term volatility.
The stock's outlook remains catalyst-driven, but near-term sentiment may stay pressured by insider-sale concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings